# A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke

> **NCT06299033** · PHASE1 · UNKNOWN · sponsor: **Hopstem Biotechnology Inc.** · enrollment: 21 (estimated)

## Conditions studied

- Chronic Ischemic Stroke

## Interventions

- **DRUG:** hNPC01

## Key facts

- **NCT ID:** NCT06299033
- **Lead sponsor:** Hopstem Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-09
- **Primary completion:** 2024-08-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299033, "A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06299033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*